[A21-69] Atezolizumab (NSCLC; first line) - Benefit assessment according to §35a Social Code Book V

Last updated 19.11.2021

Project no.:

Commission awarded on 21.05.2021 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:


First-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression ≥ 50% tumour cells (TC) and who do not have EGFR mutant or ALK-positive NSCLC

Result of dossier assessment:

Added benefit not proven.


After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

The current version 2.0 of the dossier Assessment replaces version 1.0 published on 2021-09-01.

Federal Joint Committee (G-BA)

2021-11-19 A G-BA decision was published.

G-BA documents on this decision


Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.


Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form